Steven R.NY
Speaker has a wealth of knowledge and expertise. Much ground covered for this complex subject matter.
59min · about 7,000 wordsDownload Transcript
13:18You as part of a compliance program. One is they want to know that you have effective lines of communication. So they want to know that if there's a problem, if there is a compliance problem, there is a way to communicate that with the appropriate authorities. Number two, that there are internal monitoring and auditing processes. So let's go back to that for a second.
13:47It's very easy to not find problems if you're not looking for problems. So both OIG and as you'll discover, everyone expects that you conduct consistent auditing and monitoring to ensure that you find problems. To the extent you do find problems, you go back in there and look for those problems again to make sure that they do not repeat. When you're doing these types of auditing and monitoring, what you also want to look at is not only that the problem was fixed, but that future problems are being fixed. So I've mentioned this thing called kappas, corrective actions and preventative actions. Everyone focuses on the corrective. So, for example, let's say you're thinking about a lab that is being collected and someone kept the test tubes outside. Well, if someone kept the test tubes outside, that's great. Put the test tubes back in. That is the correction. But how do you know that someone doesn't keep test tubes outside all the time? And what you might find out, for example, is that the fridge is always overcrowded. Well, maybe you need to get a new fridge and the prevention might be buying a new refrigerator.
14:55Telling someone, put the test tube back in may not fix the problem on a continuing basis. What I was describing was an example of an FDA thing, because it's easier to visualize. But you might be seeing billing issues as well. And billing issues would be an example of monitoring and auditing problems. So we talked about having internal monitoring and auditing. The next thing to ensure is that you have appropriate training and education. And what does that mean? You need to have a system to actually make sure that if you have the appropriate policies in place, those policies are being appropriately adhered to.
15:32So what do I mean by that? You basically need to ensure that you have policies that tell you what to do and what not to do. Once you have those policies, you need to make sure that people get trained on those policies. So is there a consistent training program? For example, we train everyone the moment they get employed, and then every six months for the first two years, and then once a year thereafter. I'm just making up a schedule. I'm not saying that's the right one. I'm just saying that's an example of one that might be your training program. Great. Now what you'll find out is as you start doing the monitoring and auditing, that may not be enough. Some of the training isn't sticking. In that scenario, you might have to retrain people. So having appropriate training and retraining processes will be important in your goal of ensuring that appropriate compliance training is taking place. The next element, and we talked a little bit about this. We talked about the effective lines of communication. Well, you also need to have someone to communicate with. So you want to have a designated compliance officer, and that compliance officer, hopefully, is part of or reports to a compliance team. Technically speaking, you usually want the compliance officer to be part of, to be the representative that comes in and reports directly to the board. And the OIG has made a point of that. But sometimes that is not possible, and you've got to consider that element as well. They sometimes want the
17:09compliance officer to be separate from the legal function. But overall, the key piece, the key takeaway, is that you want a compliance officer to be there, someone that people can talk to and say, I have a concern. As we'll discover in other communications, there are other elements associated with having a designated compliance officer. And what that means is this person needs to be appropriately qualified to serve as a compliance officer. And what do I mean by that? It may be via degrees, it may be by experience, it may be via training. This person needs to be appropriately qualified. Putting someone in there and calling them a compliance officer is setting them up for failure. And let's be clear, there are people who are now being targeted by the Department of Justice. You see compliance officers actually becoming targets of the Department of Justice for failure to comply.
18:11So keep that in mind as well. So we talked about having these effective lines of communication. We talked about having internal monitoring and auditing. We talked about having effective training and education, and we talked about there being a designated compliance officer and compliance committee. However, in the end, all of this works as long as there are well publicized disciplinary guidelines and enforcement. So if people don't believe that this compliance will take, if people think compliance is just something that they have to pass so that they can do their job and not something that is part of their job, that becomes a continuing problem. So you need to make sure that there is a consistent process to ensure that
19:03not only are there written procedures like discussed here, but also they are effectively communicated right here, just like this, that these written procedures are publicized, that there is a way of actually training on them, that there is a monitoring process to ensure that the training is taking, that there is a person that people can talk to. Now that we've talked about having the six processes associated with being six elements of OIG compliance, what you do want to talk about next is having a corporate compliance process. And as you will see, having a corporate compliance process involves multiple elements. And we'll talk about each one of them individually. Let's start by talking about the individual groups.
20:03The DOJ has come out and they want you to have a corporate compliance program in the event that individuals do not follow the corporate compliance program. They want to make sure that you have a compensation clawback program. And if appropriate, they want to make sure that there is a voluntary self disclosure process in the event that becomes necessary. We'll talk about each one of these individually. So let's start by talking about this element, which is on March 2023, the US Department of Justice Criminal Division came out and they updated their requirements and their recommendations for having a corporate compliance program.
20:50Lisa Monaco from the DOJ basically came out and said that both civil and criminal enforcement has three primary goals. They want to hold corporate and individual wrongdoers accountable. They want to incentivize compliance, self disclosure, remediation and cooperation. And they want to deter and penalize repeat bad actors. So I'm going to repeat that back to you. They want to hold corporate and individual wrongdoers accountable. They want to incentivize compliance, self disclosure, remediation and cooperation. And they want to deter penalizing bad actors. And she said this in the context of a program I'm going to talk about a little bit later in the context of mergers and acquisitions and how they are evaluating companies to ensure that they meet these higher goals and higher standards.
21:52So let's talk about the corporate compliance program. Just to be clear. It is a significant document. It's quite large. But I want you to take away the key element of that. And the key element is that the DOJ wants to make sure that you have a well designed corporate compliance program. This well designed corporate compliance program is being applied earnestly. So first of all, let's make sure that the program itself is good. Now, you might be able to get a program from the books. You can literally buy a book of programs, and that's great. But just because it exists doesn't mean it's appropriate for you. So make sure that it applies to you.
22:37It's been personalized to you that it works for you. And if you are doing an M A transaction, you make sure that the target company has a well designed compliance program already in place. You want to make sure that this program is being applied earnestly and in good faith. So the best program in the world doesn't work if you have no way of ensuring that it's being applied properly. So you want to make sure it's being applied earnestly and in good faith. And to make sure that happens, is you want to make sure that the program is adequately resourced and the people are appropriately staffed and empowered to function correctly.
23:16So if you have a $20 billion company, you have one corporate compliance person, and this person is in charge of 20 countries and 15,000 people. Well, the best compliance program cannot achieve that. So is this person being appropriately authorized? And let's say this person is a manager level person, has no direct visibility to the CEO or the board. The DOJ necessarily will consider that to be problematic. So you want to make sure that they have appropriate, the corporate program you have designed is being applied earnestly and in good faith. And then finally, so you have a well designed program. It's being applied earnestly and in good faith. And then lastly, that works in practice. Now, the best design program, even if you want it to be applied earnestly, if it doesn't work in practice, if you have no way of ensuring that the company is going to go in there and make sure that it works with that specific company, you're going to have a problem.
24:28So you want to make sure that the corporate compliance program works for the company in question.
24:37So we discussed a few seconds ago that they want to have a corporate compliance program that if you are going to, they being the Department of Justice wants to ensure that companies who are buying another company ensure that there is a good corporate compliance program to the extent they have a good corporate compliance program that works. But what happens if that compliance program doesn't work? In those scenarios, the Department of Justice wants to make sure that you, if appropriate, voluntarily self disclose. And what does that actually mean? They want you to. Voluntary self disclosure must be timely and voluntary, and you will not only go after the program itself, but you will go after the employees. So voluntary self disclosure only works. And the Department of Justice will consider this in a good light only if it's made voluntarily by the company. So it's not after the DOJ came in and said they found something, you went out proactively and reached out to the DOJ.
25:45If there's a pre existing obligation to disclose that would not qualify under the voluntary self disclosure program. If there was a regulation that required it, a contract that required it, or a prior department resolution, such as a deferred prosecution agreement or a non prosecution agreement, that's not going to be favorable to you. That's not going to give you these presumptive rights that we're going to discuss. So it must be voluntary. Number two, the timing must be right. So a disclosure will only be deemed to be voluntary if it is prior to an imminent threat of disclosure or government investigation. So if you know that the investigation is coming and you decide to voluntarily self disclose, that may not be good enough.
26:39And this disclosure must be prior to the misconduct being publicly disclosed or otherwise known to the government and within a reasonably prompt time after the company became aware of the misconduct, with the burden being on the company to demonstrate timeliness. For a disclosure to be deemed a voluntary self disclosure, all relevant facts concerning the misconduct that are known to the company must be made. There were certain advantages that they talked about in the previous version. In March, they talked about certain advantages. I'm not going to get into those advantages because there's a new update, and we'll talk about the new update.
27:20Specifically on October 4, the Department of Justice came out with this new safe harbor for voluntary self disclosure made in connection with mergers and acquisitions. So they actually talk about this fact that there was an antitrust issue that they had involving two pharmaceutical companies, Teva and Glenmark, and they determined that a monetary penalty alone was not sufficient. In that specific instance, they actually made the company divest, a widely used cholesterol medication that was a core part of the company's process. And this was the first time a divestiture was required as part of a corporate criminal resolution.
28:08As we discussed a few seconds ago, in 2023, in March 2023, every DOJ component is now required. Every component of the DOJ basically came out and said that they want to have a corporate criminal enforcement program, and they want to have a voluntary self disclosure policy. And the DOJ wants prompt disclosure of this misconduct in a timely manner to take advantage of these programs moving forward. They specifically focus on mergers and acquisitions and acquiring companies that promptly and voluntarily disclose criminal misconduct within the safe harbor period and cooperate with the ensuing investigation and engage in requisite, timely and appropriate remediation.
29:00Restitution and discouragement will receive a presumption of declination. Which means what? It means that if you come out, you voluntarily self disclose, you say, we made a mistake, we had a mere culpa. The Department of Justice will look at you favorably. They will actually, per se, they will work with a presumption to decline an action against you. But again, to qualify for this, there are certain conditions. Companies must disclose misconduct within six months from the date of closing of the acquired entity. This applies whether the misconduct was discovered pre or post acquisition. Now, companies then have a baseline of one year from the closing date to fully remediate the misconduct. Now, that doesn't mean it's always one year. Again, you have a little bit of bandwidth, a little bit of wiggle room. You can have a conversation.
29:53But that conversation, you need to start from somewhere, which is why they start with the one year. And on top of this, the fact that they're giving you the safe harbor. This misconduct will not be factored into future recidivist analysis of the acquiring company. So if you have a scenario where more problems are found, they're not going to refer back to this and say, oh, this is your second time, your third time, your 50th time. On the other hand, if the company does not perform effective due diligence and does not self disclose misconduct, it will be subject to full success or liability for that misconduct.
30:32So that is something to be aware of. That is something to be afraid of. So, companies, if you are engaged in an M A transaction, it is appropriate to do an appropriate due diligence. Find out if there are any problems. I will tell you that based on what I've seen, it is rare for smaller entities to have a corporate compliance program. It is rare for smaller entities to have an OIG compliance program. You may need to build each of those. In a global world like the one we deal with right now, you might be looking at FCPA issues. What you need to start thinking about is you have a false claims act problem. You might have a FCPA problem. You might have a corporate due diligence problem, all of which will need to be under the auspices of this general compliance build. You might start by building this general compliance program and then have an element of, say, FCPA. That's part of it. You might have the FCA, the False Claims act element, that's part of it, et cetera, et cetera, et cetera. So make sure that you have all these elements considered into how you are going to build your overall compliance program. Now, we talked a little bit about this voluntary self disclosure as part of that process. Again, when entering into criminal resolutions, companies will be required to implement a compliance related criteria into their compensation and bonus system and to report to the division of the Department of Justice such implementation during the term of the resolution. So this again came out of a pilot program from March 2023 and
32:23in that scenario, basically they said that we don't want you to just point out that there were problems. We actually want you to go further. What we want you to do is to name blame and shame. We want you to point out people who caused the problems. We want you to hold individuals responsible and if appropriate, take back monies that were given to them. So it directs division prosecutors to consider fine reductions where companies seek to recoup under this program. Essentially, if the company seeks to recoup compensation from culpable employees,
33:04then that could be seen favorably. This includes both those who were actually culpable, but also those who had supervisory authority over the employees or business area engaged in the misconduct and knew or were willfully blind to the misconduct. Now what you're going to see is this is a continuing program, a continuing process, a continuing theme going across the different compliance programs we talk about. So it's not just the person who made the mistake, it's the person who is, for example, their boss that should have known that this mistake could be made. And again, how do you actually have this compensation? Clawback, you might be looking at a prohibition on bonuses for employees who do not satisfy compliance performance requirements, disciplinary measures for employees who violate applicable laws.
34:03If there are individuals who have supervisory authority and are engaged in misconduct, well, they will be held responsible, too. On the other hand, they do actually recommend that those employees who demonstrate full commitment to the compliance process may get incentivized. So keep that in mind as well. Maybe that's a way of actually providing a bonus to those individuals. So essentially, this pilot program started in March 2023, and it rewards companies that claw back or withhold incentive compensation from executives responsible for misconduct or attempt to do so in good faith.
34:41So for every dollar that a company claws back withholds from an employee who engaged in misconduct or a supervisor that they knew turned a blind eye to it, the company will deduct a dollar from the otherwise applicable penalty that the resolving company would otherwise pay. So essentially, again, if you pull back the money or you refuse to give the money for someone who either knew or should have known about this misconduct, you will be financially incentivized. According to the DOJ, at a practical level, I think companies are still struggling with this. You need to have the processes in place. But if you are an acquirer, you're coming in with a fresh set of eyes.
35:25You're coming in with this idea of I don't want to be held responsible, I don't want to have success or liability. Each of these needs to be considered.
35:35So we talked a little bit about the OIG system. We talked a little bit about the corporate compliance program. Now, recognize the fact that the OIG and the corporate compliance program basically work off of the same structure, which is you want to have clear processes, you want to have someone to report those processes to, and you want to have a way of ensuring that those processes are followed. We'll talk a little bit about that because you're going to see the same exact elements follow through in the FDA regulatory compliance piece as well. So we're going to talk next about the FDA regulatory compliance piece.
36:16Depending on what type of regulatory compliance you're thinking about, you might be looking at drug, device, cosmetic, food, or pharmacy due diligence. So if you're buying a compounding pharmacy, you're buying a company that manufactures food, you're looking at a cosmetic manufacturing company, a medical device manufacturer, a drug manufacturer. Each of these will need their own unique regulatory review because there are different regulatory processes in place. Nevertheless, we'll sort of focus primarily on devices and drugs only because they tend to be a little bit more complicated than the rest of them. So if you can get a sense of what it looks like for devices and drugs, it should flow over. You'll just sort of have a slightly stripped down version with additional components latched on. So we talked a little bit about having a quality program.
37:13That quality program will apply to different elements. You might decide to focus on one or the other. If you're looking at manufacturing, that's going to be throughout the drug or devices lifecycle? Lab practices generally will be early on. If you're discovering a drug, though, you will see the lab actually continue throughout. If you are looking at just the quality assurance program, you want to make sure that they have a good distribution program. How do you make sure that the distributors are appropriately registered? How do you make sure that they keep your product, the finished product, in a way that does not render the product adulterated or mislabeled or misbranded?
37:54If this company is still doing clinical research, are they following gcps, good clinical practices? And we'll talk about that a little bit more as well. Do they have a pharmacovigilance program? Do they make sure that if there are any adverse events, those adverse events are being appropriately reported? Are they conducting any kind of marketing? Are those marketing programs consistent with the FDA's near constantly evolving marketing standards? There have been a series, a slew of changes from the FDA since 2011 2012 around what can be said and what cannot be said. As late as earlier this week, the FDA released a new guidance on off label communications of products. So all of these are going to play a huge role, whether you're talking about consistent with label, off label communications, on label communications, or just scientific discussion, all of which will get slightly different levels of scrutiny, slightly different levels of interest.
38:58And if you are auditing the company, if you're going to buy the company, it behooves you to know what you're walking into. So the next thing to look at is, again, what are the elements of a quality program? To have a quality program, you have what's called the Plan do Check act, or the Plan do Study act system. It might also be called the Shoehart or the Deming cycle, came out from Tokyo Institute of Technology, 1959. But it's a way of. So you'll see PDCA for plan, do check act. You'll see PDSA for plan, do study act, et cetera. But this is used as far back 1959, used by Motorola and used by several other large companies. But it's a way of continuous product improvement. And again, we talked a little bit about these different programs and how they exist.
39:54What is also important to recognize is that these companies are often in a place where they are, how should I put this?
40:11The compliance programs we discussed and these quality programs we discussed, there are consistencies in how they would be engaged. So, for example, we talked about planning. So that's kind of scoping out what you need to do. Doing that might be writing out those sops. We were talking about checking. That's your audits. And as a result of those audits, you'll act. You'll actually fix what you found to be the problem. So this is in line with everything else that both the DOJ and the OIG have been talking about so far.
40:49As we discussed, there are different types of FDA audits. You might do FDA analysis that you might do. In 2022, the FDA issued 62 warning letters, 23 import alerts just related to drugs, and they did a bunch of different onsite inspections. And 42, which is about 67% of the warning letters followed onsite inspections. While there were some that were just resulting from records requests, there were 483s as well. So we talked a little bit about warning letters. So if you remember earlier, we talked about titled and untitled letters. Those sort of less important than your warning letters would be like the. There were 466 four eightyz issued in 2022 compared to 215 in 2021. So as you can tell with something like that, Covid slowed down the number of 483s that were issued medical devices, you had 24 different warning letters that played in. So to do all of this to make sure you avoid problems with manufacturing, the FDA basically wants you to have six elements in place. They want to make sure that you have a quality program.
42:12They want to make sure that you have controls for production, they want to make sure you have controls for facilities and equipment, they want to make sure that you have lab controls, they want to make sure that you have material controls, and they want to make sure that you have packaging and labeling controls. Nevertheless, the FDA found that between 2018 and 2022, the following were the biggest problems they found on a consistent basis. Number one, the procedures. There were no written procedures in up to 525 different audits that they did, that the production record review was inconsistent. That was seen in 505 different audits. The lab controls were problematic in about 453 audits, that there were inadequate written procedures. Production and process controls seen in 278 audits.
43:00The testing program for the stability of the drug products was inadequate in 273 different situations. And that's just the top five. And we could keep going. There are several more. But what that tells you is the importance that the FDA gives to manufacturing and why it behooves you when you're trying to buy a company, to possibly have a third party do a manufacturing audit. If that has not been done recently, if it has been done recently, maybe it makes sense to just say, can I see a copy of that? But it's important to recognize not just seeing a copy, but also looking at what was done as a result, as a response to the audit that was done.
43:42So if you are an acquirer, it's not sufficient just to go, oh, was an audit done well? Did they fix it? Was the fixing adequate? Were the issues closed out? All of which should be considered. So when you're talking about clinical research, for example, in those situations, you might be looking at a bunch of different documents. So you'll see this very often in what are called phase one, phase two types of studies in companies that are engaged in phase one, phase two. In those situations, you might be looking at the protocol, you might be looking at investigator agreements, you might be looking@the.org charts. You might be looking at correspondence with the DOJ sponsor, et cetera. You might be looking at CRO vendor agreements.
44:26This is very big. They want to look at device accountability records. You want to look at the monitoring plan. And are those being followed? Are the monitors and the clinical investigators appropriately qualified? What are the training records? What are the subject records. Do you have access to those subject records? Who owns that data? Might be an important question. We talked a little bit later about pharmacovigilance, but are there any adverse drug effects that you need to be considering? Are there appropriate standard operating procedures in place?
44:58The FDA looked into these issues. I'm going to talk primarily about sponsor findings because a lot of my clients do tend to be sponsors in those scenarios. But there are versions you'd look at if you're doing, for example, a clinical trial site and you're going to audit them, you're going to buy them, you need to know what you're looking at. Sponsors were found to have inadequate monitoring, failure to secure investigator compliance. So they're basically not making sure they're not doing a good job making sure that the principal investigator conducting the clinical research is appropriately supervising the work. They're not appropriately submitting progress reports to the FDA as necessary.
45:39They're not appropriately looking into adverse events, that they're not appropriately notifying the FDA investigators or irbs. They don't have full control of the devices in play, that they fail to obtain investigator agreements. So the form 1572 is not appropriately signed. They fail to get IRB approval. That the individuals in questions are in question are unqualified monitors. That would be problematic as well. So you're sending in monitors to make sure that everyone's following the rules except the monitor themselves is not adequately qualified, that you're losing track of the devices that you've sent out to be studied, that there is inadequate result disclosure, which might be a huge problem, because, again, if you're buying a company that is not appropriately disclosing its results, the penalty can be $20,000 per day per study. That's $20,000.
46:44It's either 10,000 or $20,000 per day per study. And that adds up very quick, as you can imagine. So we talked a little bit about clinical research, we talked a little bit about labs. We talked a little bit about manufacturing. Another big area that you might be looking at is marketing. And there are FDA considerations. There are OIG considerations, there are CMS considerations. When you're talking about FDA considerations, you're thinking about,
47:16and OPDP is talking about things like fair balance. And when you see those drug ads, are those being appropriately managed? But it's also getting into are your sales reps doing the right things? When you're talking about CMS and OIG, you might be thinking about the disclosures that are necessary under the Sunshine act. And then we're talking about OIG, you're thinking about kickbacks, you're thinking about corporate integrity agreements. So, for example, you might be in a scenario where the company is subject to a corporate integrity agreement, and that's an agreement with the Department of Justice. You might be in a scenario where you are in violation of the False Claims act, and we'll talk about what that could look like. You might be in a scenario where kickbacks were being given to doctors and that exposes you to significant liability.
48:04Stark is actually not as big a concern in the pharma world or the device world. It's more of a concern when you are one hospital buying another hospital, or a hospital with a doctor site, or hospital with a lab. This is less of a concern here. And this is again, you'll see the same thread going through. You might be looking at the park doctrine. The park doctrine or the responsible corporate officer doctrine. It allows for criminal prosecution and imprisonment of an individual who was not personally involved or not aware of corporate misconduct. So this actually came out of a case went all the way to the Supreme Court of John park, who was the president of a national food chain. He was convicted of a food, Drugs and Cosmetics act misdemeanor violation for rodent contamination in the company's warehouses. Again, park, being the CEO, goes, I didn't have any direct responsibility for sanitation, but he was, as the president, indirectly responsible for overall operations. The Supreme Court basically came out and said that consistent with its USB daughter wike determination or decision, an individual can be held criminally liable for a food, drugs and cosmetics act violation without consciousness of some wrongdoing. So as long as he bears a responsible relation to or has a responsible share in the violation. So again, if you are buying a company, you have to recognize that as you buy the company, you might be subject to park doctrine violations, and you want to make sure that those types of issues are either being found,
49:49addressed, disclosed, or otherwise managed. This was an example of the types of penalties that were being paid out all the way to 2017. As you can tell, you are looking at $5 billion in damages, $3.4 billion in damages, $6.5 billion in damages. As you can tell, it sort of dropped off a little bit, primarily because the FDA itself has had to recalibrate the types of penalties that are appropriate for off label communications. This has resulted from the Supreme Court decisions involving IMSV Sorrell, but there were other decisions as well coming out of the second Circuit, for example, in the Alfred Corona case, and we can talk about those if you guys want to reach out.
50:36But again, this represents both an opportunity for companies that are saying, you know what, I want to talk about these advantages associated with my product, but that are not appropriately studied or that are appropriately studied but have not been submitted to the FDA. Alternatively, I want to avoid people saying things that are inappropriate because of the types of fines and penalties I might be looking at. So I just want to be clear that just because there's been a drop up, it does not mean that it has stopped. You are seeing consistent penalties all the way through to today. This was just something that was easy and accessible.
51:16There are, again, privacy concerns. I'm not going to do a deep dive into privacy, but I did want to bring it up as a concept. You do want to consider things like, am I going to look at just the US privacy issues, or am I going to look at ex us? Am I going to look at just federal? So, for example, HIPAA considerations, or am I going to look at state laws? So, for example, if you're thinking of California, am I going to start thinking about CCPA and CPRA? But you might also consider things like CMEA, which a lot of people don't know exists, which is for medical data. If you're talking about medical data, are you going to think about just that?
51:51Or is the data itself non medical? So it's not so much the content that matters, it's who was given the information and what context. So, for example, if you disclose that information in the context of recruitment at a regular website, even though the data itself may have medical implications, it may not be subject to HIPAA, and that becomes a consideration. You also want to look at the issue of data privacy, which is governed, for example, by HIPAA. But data ownership is not quite covered by HIPAA. In the same way you might be looking at GDPR, which does talk about data controls. But again, ownership is a very different situation, and often companies avoid that, avoid discussing it. So you may want clarity, if that is the goal, if that is the reason. So I've been in a situation where someone was looking at buying a company for the data. Turns out that the company didn't actually own the data. It is a huge consideration to keep in mind. You might also be looking at cybersecurity.
52:52The FDA has been demonstrating a consistent push in the direction of data security and data privacy and cybersecurity. The other things to think about when you're buying the company, and I've been involved in these situations as well, where you bought the company, the company belongs to you but you don't know how to get access to the data because you might have ownership of the data, but no access to the data because the company was a result of bankruptcy. Well, what do you do then? You might have a situation where you have access to the data. It's in your computer, but you don't know the passwords. Make sure that that's covered in the agreement that you sign.
53:36So in that spirit, what you want to start thinking about is you want to get a summary of findings. When you put that summary together, you want to again, start out by saying, this is the scope of everything we looked at. Just as importantly, this is what we did not look at. So that way there's clarity on what was considered, what was not considered. Then you give a quick summary of findings. So here's what we found. You want to be as objective as possible. This is not where you start giving out too many sort of opinions, because unless it's very fact based, to the extent you can be, or you're speaking specifically about your takeaway, but the more you speak non objectively, you speak subjectively, the more problematic it can be because that goes to interpretation.
54:27But again, there's nothing inherently wrong with it. You just want to make sure you keep that in mind. And then what you also want to talk about is what is that summary of findings based on what documents were actually reviewed, all of which are useful in putting out a summary of findings in the context of a regulatory analysis. Then we can talk about post due diligence and in the post due diligence phase. So you've done the due diligence, you've actually provided the report. This report is going to have a dramatic impact on the contract that is going to be signed. Often it's just one piece of the contract, but it's a very important piece because that is the entire reason that the company is being bought. So you want to keep aware of that in the contract drafting phase and recognize that what you do will have an impact on the post m a integration phase.
55:18So in the context of the contract drafting, you want to look at the definitions. For example, the definition of health law is going to be one that comes up quite often. You want to make sure that you define it appropriately as the acquirer. You may want it to be broad, the acquired company will definitely want it to be narrow, but that push and pull is what's going to have to happen. You're going to talk a little bit about data. So this becomes important because people will try to include data as part of IP, and more often than not, data is not part of the IP you're thinking of. So you want to have a separate data ownership data access clause in there as well. Some other considerations are patients involved? So you have to be, again, aware of things like beneficiary inducement considerations, and that can come up into play. And again, you might have to disclose that if appropriate. Is a physician involved? In which case are there physician ownership issues?
56:20And this can implicate, again, stark law. It can implicate kickback issues. Is the sunshine act going to be something you consider? So again, goes to the disclosure issues that need to happen. And then speaking of disclosure, are you going to put something in there around, say, clinical trial reporting? Like I mentioned, the penalties can be quite significant in the tens of thousands of dollars per day per study. So keep that in mind as well. We talked a little bit about the contract drafting. Let's now talk about the post integration phase. So in that scenario, you want to be aware that there needs to be an overall compliance program, especially when you're buying a smaller company. An overall compliance program may not be as easily available in the smaller company, so you may need to develop that.
57:11As part of that, you may need to do your own analysis. And when you're doing that analysis, you're going to find problems. Are those problems things that you need to disclose? Keep that in mind, because if you do disclose them and you get non prosecution, that's great. You want to bring the appropriate stakeholders to the table. Very often you will see regulatory review where a junior manager gets involved, and that's fine if they're appropriately qualified to take it to the right stakeholders. Sometimes it's just easier to bring all the right stakeholders to the table so that the appropriate compliance program can be put into place and that can be executed. You want to have a risk based plan of action. So just because you will often find when you're creating a compliance program that there are 50 things you can go after. It makes sense to start saying, here are the top five you're going to look at, or the next five we're going to look at. Just because you can't attack everything at the same time, you need to have a way of actually reporting to the key stakeholders, tell them what's happening, and finally, again, have a way of analyzing if compliance is being achieved and if appropriate, if compliance is not being achieved, reporting that to the key stakeholders and or government entities as is appropriate.
58:29Again, my name is Darshan Kulkarni. I'm principal attorney at the Kulkarni law firm. Hopefully this added some value to the next m a transaction involving an FDA regulated company. I hope you feel free to reach out to me if I can answer any questions, and I look forward to hearing from you.
Steven R.NY
Speaker has a wealth of knowledge and expertise. Much ground covered for this complex subject matter.
Nina F.IL
Superb and general caveats discussed may be applicable to issues related to other types of M7 A transactions. Outstanding , comprehensive presentation. Highly recommended.